amonafide malate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: amonafide malate
• 英文别名: Xanafide；5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione;2-hydroxybutanedioic acid
• 化学式: C₄H₆O₅*C₁₆H₁₇N₃O₂
• 分子量: 417.419
• InChiKey: JNZBHHQBPHSOMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.49
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  162
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  mitonafide malate 在 palladium-carbon 作用下， 以 水 为溶剂， 生成 amonafide malate
  参考文献：
  名称：

  US2005/239816

  摘要：

  公开号：

文献信息

• COMPOUNDS AND METHODS FOR TREATMENT OF CANCER
  申请人：Sudhakar Anantha

  公开号：US20110105497A1

  公开（公告）日：2011-05-05

  Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using the compounds together with another chemotherapy, radiation therapy, hormonal therapy, biological therapy, or immunotherapy. Pharmaceutical compositions suitable for use in the methods are also disclosed.

  揭示了用于治疗、预防或管理癌症的化合物。还提供了使用这些化合物治疗各种癌症的方法。同时还提供了使用这些化合物与另一种化疗、放疗、激素疗法、生物疗法或免疫疗法结合的治疗方法。还公开了适用于这些方法的药物组合物。
• Amonafide salts
  申请人：Xanthus Life Sciences, Inc.

  公开号：US20030203932A1

  公开（公告）日：2003-10-30

  Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): 1 R1 is —(CH 2 ) n N + HR3R4 X − or R1 is —(CH 2 ) n N + HR3R4 X − or —(CH 2 ) n NR3R4 when R2 is —N + HR6R7. R2 is —OR5, halogen, —NR6R7, —N + HR6R7 X −, sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X − is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).

  本发明涉及一种氨酰胺或氨酰胺类似物的盐，其结构式（I）表示为：1R1为—（CH2）nN+HR3R4 X−或R1为—（ ）nN+HR3R4 X−或—（ ）nNR3R4，当R2为—N+HR6R7时。R2为—OR5、卤素、—NR6R7、—N+HR6R7 X−、磺酸、硝基、—NR5COOR5、—NR5COR5或—OCOR5；R3和R4独立地为H、C1-C4烷基或与它们结合的氮原子一起形成非芳香族含氮杂环基；每个R5独立地为—H或C1-C4烷基；R6和R7独立地为H、C1-C4烷基或与它们结合的氮原子一起形成非芳香族含氮杂环基；n为0-3的整数；X−是有机羧酸化合物的羧酸根阴离子。还公开了制备某些结构式（I）所表示的化合物的方法。
• Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
  申请人：Brown M. Dennis

  公开号：US20050113579A1

  公开（公告）日：2005-05-26

  The present invention concerns novel methods for the synthesis of naphthalimides and mitonafide analogs, as well as salts thereof. Also included are novel compositions, including naphthalimides and naphthalimide salts, analogs thereof, as well as stable liquid dosage forms thereof.

  本发明涉及一种合成萘酰亚胺和米托那菲类似物及其盐的新方法。还包括新的组合物，包括萘酰亚胺和萘酰亚胺盐，其类似物以及其稳定的液体剂量形式。
• (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of antecedent hematologic disorders
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP2649997A1

  公开（公告）日：2013-10-16

  The invention provides SNS-595 for use in a method of treating myelodysplastic syndrome, including chronic myelomonocytic leukemia. The treatment with SNS-595 may be combined with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the treatment comprises administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

  本发明提供了用于治疗骨髓增生异常综合征（包括慢性粒细胞白血病）的 SNS-595。SNS-595的治疗可与化疗、放疗、激素治疗、生物治疗或免疫治疗相结合。在某些实施方案中，治疗包括 SNS-595 与阿糖胞苷联合应用。此外，还公开了适用于上述方法的药物组合物和单一单位剂型。
• Engineered platelets for targeted delivery of a therapeutic agent
  申请人：JPV01 LTD.

  公开号：US11518796B2

  公开（公告）日：2022-12-06

  The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

  本发明提供了具有所需靶向特异性嵌合血小板受体（CPR）的工程血小板。此外，人造血小板可包含货物，货物可在血小板活化时释放。此外，血小板可由巨核细胞体外生成，以产生非血栓性血小板。